RARE Ultragenyx

USD 46.59 -0.78 -1.646612
Icon

Ultragenyx (RARE) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 46.59

-0.78 (-1.65)%

USD 3.30B

0.85M

USD 72.40(+55.40%)

USD 52.00 (+11.61%)

Icon

RARE

Ultragenyx (USD)
COMMON STOCK | NSD
USD 46.59
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 3.30B

USD 52.00 (+11.61%)

USD 46.59

Ultragenyx (RARE) Stock Forecast

Show ratings and price targets of :
USD 72.40
(+55.40%)

Based on the Ultragenyx stock forecast from 4 analysts, the average analyst target price for Ultragenyx is USD 72.40 over the next 12 months. Ultragenyx’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ultragenyx is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Ultragenyx’s stock price was USD 46.59. Ultragenyx’s stock price has changed by -3.96% over the past week, -4.76% over the past month and +20.92% over the last year.

No recent analyst target price found for Ultragenyx
No recent average analyst rating found for Ultragenyx

Company Overview Ultragenyx

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationa...Read More

https://www.ultragenyx.com

60 Leveroni Court, Novato, CA, United States, 94949

1,311

December

USD

USA

Adjusted Closing Price for Ultragenyx (RARE)

Loading...

Unadjusted Closing Price for Ultragenyx (RARE)

Loading...

Share Trading Volume for Ultragenyx Shares

Loading...

Compare Performance of Ultragenyx Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for RARE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Ultragenyx (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +3.69 (+0.91%) USD90.49B 26.38 17.57

ETFs Containing RARE

Symbol Name RARE's Weight Expense Ratio Price(Change) Market Cap
GNOG:LSE
Global X Genomics & Biote.. 4.72 % 0.50 % 0.00 (0.06%) USD7.58M

Frequently Asked Questions About Ultragenyx (RARE) Stock

Based on ratings from 4 analysts Ultragenyx's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on RARE's stock to indicate if its a good dividend stock.

Based on targets from 4 analysts, the average taret price for RARE is USD 72.40 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 48.

Unfortunately we do not have enough data on RARE's stock to indicate if its overvalued.

The last closing price of RARE's stock was USD 46.59.

The most recent market capitalization for RARE is USD 3.30B.

Based on targets from 4 analysts, the average taret price for RARE is projected at USD 72.40 over the next 12 months. This means that RARE's stock price may go up by +55.40% over the next 12 months.

Following are ETFs with the highest allocation to Ultragenyx's stock :

GNOG:LSE

As per our most recent records Ultragenyx has 1,311 Employees.

Ultragenyx's registered address is 60 Leveroni Court, Novato, CA, United States, 94949. You can get more information about it from Ultragenyx's website at https://www.ultragenyx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...